Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment
- PMID: 40312419
- PMCID: PMC12045981
- DOI: 10.1038/s41392-025-02226-7
Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment
Abstract
The gut microbiota crucially regulates the efficacy of immune checkpoint inhibitor (ICI) based immunotherapy, but the underlying mechanisms remain unclear at the single-cell resolution. Using single-cell RNA sequencing and subsequent validations, we investigate gut microbiota-ICI synergy by profiling the tumor microenvironment (TME) and elucidating critical cellular interactions in mouse models. Our findings reveal that intact gut microbiota combined with ICIs may synergistically increase the proportions of CD8+, CD4+, and γδ T cells, reduce glycolysis metabolism, and reverse exhausted CD8+ T cells into memory/effector CD8+ T cells, enhancing antitumor response. This synergistic effect also induces macrophage reprogramming from M2 protumor Spp1+ tumor-associated macrophages (TAMs) to Cd74+ TAMs, which act as antigen-presenting cells (APCs). These macrophage subtypes show a negative correlation within tumors, particularly during fecal microbiota transplantation. Depleting Spp1+ TAMs in Spp1 conditional knockout mice boosts ICI efficacy and T cell infiltration, regardless of gut microbiota status, suggesting a potential upstream role of the gut microbiota and highlighting the crucial negative impact of Spp1+ TAMs during macrophage reprogramming on immunotherapy outcomes. Mechanistically, we propose a γδ T cell-APC-CD8+ T cell axis, where gut microbiota and ICIs enhance Cd40lg expression on γδ T cells, activating Cd40 overexpressing APCs (e.g., Cd74+ TAMs) through CD40-CD40L-related NF-κB signaling and boosting CD8+ T cell responses via CD86-CD28 interactions. These findings highlight the potential importance of γδ T cells and SPP1-related macrophage reprogramming in activating CD8+ T cells, as well as the synergistic effect of gut microbiota and ICIs in immunotherapy through modulating the TME.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics: Experiments were conducted in compliance with all relevant governmental and institutional guidelines and regulations. All animal procedures were approved by the Institutional Animal Care and Use Committee of West China Hospital, Sichuan University (Approval No. 20220301038).
Figures








Similar articles
-
Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma.Front Immunol. 2024 Jun 10;15:1401967. doi: 10.3389/fimmu.2024.1401967. eCollection 2024. Front Immunol. 2024. PMID: 38915399 Free PMC article. Review.
-
MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody.Gut Microbes. 2024 Jan-Dec;16(1):2380061. doi: 10.1080/19490976.2024.2380061. Epub 2024 Jul 30. Gut Microbes. 2024. PMID: 39078050 Free PMC article.
-
Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC.J Transl Med. 2024 Dec 30;22(1):1157. doi: 10.1186/s12967-024-06018-5. J Transl Med. 2024. PMID: 39736762 Free PMC article.
-
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.Gut Microbes. 2025 Dec;17(1):2452277. doi: 10.1080/19490976.2025.2452277. Epub 2025 Jan 18. Gut Microbes. 2025. PMID: 39826104 Review.
-
Blautia coccoides and its metabolic products enhance the efficacy of bladder cancer immunotherapy by promoting CD8+ T cell infiltration.J Transl Med. 2024 Oct 24;22(1):964. doi: 10.1186/s12967-024-05762-y. J Transl Med. 2024. PMID: 39449013 Free PMC article.
Cited by
-
Pro-repair macrophages driven by CGRP rescue white matter integrity following intracerebral hemorrhage.J Neuroinflammation. 2025 Jun 21;22(1):161. doi: 10.1186/s12974-025-03483-7. J Neuroinflammation. 2025. PMID: 40544251 Free PMC article.
-
Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1-NUDT15 Loss.MedComm (2020). 2025 Sep 1;6(9):e70361. doi: 10.1002/mco2.70361. eCollection 2025 Sep. MedComm (2020). 2025. PMID: 40904703 Free PMC article.
-
Advancements in understanding tumor-resident bacteria and their application in cancer therapy.Mil Med Res. 2025 Jul 25;12(1):38. doi: 10.1186/s40779-025-00623-1. Mil Med Res. 2025. PMID: 40713785 Free PMC article. Review.
-
Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025.Front Microbiol. 2025 Aug 6;16:1623875. doi: 10.3389/fmicb.2025.1623875. eCollection 2025. Front Microbiol. 2025. PMID: 40842839 Free PMC article.
-
Ultrasound-enhanced Pt-coordinated polymer immunopotentiators and heterogenic fusion membrane-based multifunctional tumor vaccine nanoplatforms for melanoma treatment.Signal Transduct Target Ther. 2025 Aug 25;10(1):278. doi: 10.1038/s41392-025-02355-z. Signal Transduct Target Ther. 2025. PMID: 40854883 Free PMC article.
References
-
- Kim, J. M. & Chen, D. S. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann. Oncol.27, 1492–1504 (2016). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous